Drugs / ATH-097
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07640269 | Jul → Oct 2026 expected | — | Atheron Therapeutics, Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATH-097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07640269 ↗ |
| Route | Oral | “Oral Suspension” NCT07640269 ↗ |